ArticleJournal of managed care & specialty pharmacy2026
Economic value of ribociclib in early breast cancer in the United States.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) experience recurrence despite treatment with adjuvant endocrine therapy; recurrences bear a substantial cost and can impact life expectancy and quality of life.
objectiveTo estimate the lifetime clinical and economic value of ribociclib for the treatment of patients with HR+/HER2- stage II/III eBC at high risk of recurrence including select node-negative and all node-positive patients.
methodsA 4-state Markov model comparing ribociclib+nonsteroidal aromatase inhibitor (NSAI) with NSAI alone estimated the expected lifetime costs and effectiveness for patients with eBC (mean age = 53 years). High risk of recurrence in HR+/HER2- eBC was based on the NATALEE trial criteria: all node-positive and node-negative patients with tumor size larger than 5 cm or 2-5 cm with Grade 3 or Grade 2 and high genomic risk. Model outcomes included invasive disease-free survival (IDFS), locoregional recurrence (LR), distant recurrence (DR), overall survival, adjuvant treatment costs, adverse event costs, disease management costs by health state, and DR treatment costs. Patient-level IDFS for the first 4.5 years observed in the NATALEE trial was parametrically extrapolated thereafter. DR and LR progression risks and treatment utilization patterns were obtained from the literature. Model outputs included total costs, quality-adjusted life-years (QALYs), life-years (LYs), equal-value LYs (evLYs), and the incremental cost-effectiveness ratio (ICER) of ribociclib+NSAI vs NSAI when using IDFS as the effectiveness outcome.
resultsRibociclib+NSAI improved IDFS (13.08 vs 11.09 years) and reduced DR (DR state = 1.28 vs 2.35 years), generating QALY gains of 0.68 (ribociclib+NSAI = 11.45; NSAI = 10.77), LY gains of 0.69 (ribociclib+NSAI = 14.98; NSAI = 14.29), and evLY gains of 0.75 (ribociclib+NSAI = 11.52; NSAI = 10.77). Total lifetime incremental costs were $52,385 (ribociclib+NSAI = $831,433; NSAI = $779,047). The ICER was $77,448/QALY, and the probability of ribociclib+NSAI being cost-effective was 68.5% at a willingness to pay of $150,000/QALY.
conclusionsBased on model estimation, ribociclib+NSAI is projected to be a cost-effective therapy in the United States vs NSAI alone by reducing the rate of high-cost metastatic recurrences and increasing QALYs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.